Fig. 2: Relative risk of having high RNA expression of T cell priming markers among different types of cancer (N = 514). | npj Genomic Medicine

Fig. 2: Relative risk of having high RNA expression of T cell priming markers among different types of cancer (N = 514).

From: T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy

Fig. 2

Relative risk compared with all other types of cancer is demonstrated. Red represents higher risk and blue represents lower risk of having high RNA expression. After Bonferroni correction, no significant differences were detected between cancers. Significant p value was defined as 0.0002 (0.05/240 variables from T-cell priming markers) or less after Bonferroni correction. P values were calculated with chi square test. Others include: cervical cancer (N = 5), bladder cancer (N = 4), gallbladder and extrahepatic bile duct cancers (N = 4), prostate cancer (N = 4), brain and nervous system cancers (N = 3), kidney and renal pelvis cancers (N = 3), squamous cell carcinoma of the skin (N = 3), thyroid cancer (N = 3), adrenal gland cancer (N = 3), lipomatous neoplasm (N = 2), mesothelioma (N = 2), basal cell carcinoma of the skin (N = 1), ocular melanoma (N = 1), primary peritoneal carcinoma (N = 1), and thymic cancer (N = 1). CUP cancer of unknown primary, H&NC head and neck cancer, LBC liver and bile duct cancer, NEC neuroendocrine cancer, SIC small intestine cancer.

Back to article page